Avalo Therapeutics Inc (AVTX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $448.71M
Last updated: Nov 17, 2026 at 4:10 PM ET
Avalo Therapeutics Inc (AVTX) Statistics
Avalo Therapeutics (AVTX) has a market cap of $448.71M and an enterprise value of $383.72M. It kept -150259.32% of revenue as net income over the last 12 months. Its share count is up 293.28% from a year earlier.
Total Valuation
Enterprise value is 14.48% below the market cap, as cash exceeds debt.
| Market Cap | $448.71M |
|---|---|
| Enterprise Value | $383.72M |
| Latest price (Nov 17, 2026) | $7.13 |
Key Dates
The next earnings report is expected on Mar 22, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 22, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 5, 2026 |
| Fiscal Year End | December |
Valuation Ratios
| P/B Ratio | 0.9x |
|---|---|
| P/TBV Ratio | 0.9x |
Price Statistics
The stock is down 52.81% over 52 weeks and trades 39.78% below its 50-day average.
| Beta (1Y) | 1.57 |
|---|---|
| 52-Week Change | -52.81% |
| 1-Month Change | -38.48% |
| 3-Month Change | -65.64% |
| 6-Month Change | -56.18% |
| 5-Year Change | -99.89% |
| 10-Year Change | -99.93% |
| Total Return (1Y) | -52.81% |
| Total Return (3Y CAGR) | -30.88% |
| Total Return (5Y CAGR) | -74.19% |
| Return vs SPY (1Y) | -71.95% |
| Max Drawdown (1Y) | -71.01% |
| Max Drawdown (3Y) | -83.62% |
| Sharpe Ratio (1Y) | -0.99 |
| Correlation with SPY (1Y) | 0.23 |
| 50-Day Average | $11.84 |
| 200-Day Average | $15.54 |
| 52-Week Range | $6.53 to $24.27 |
| RSI (14 Days) | 34.7 |
| Average Volume (20 Days) | 3.35M |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 16.63x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 16.63x |
|---|---|
| Quick Ratio | 16.63x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on equity is -20.31% and return on assets is -18.41% over the last 12 months.
| Return on Equity (ROE) | -20.31% |
|---|---|
| Return on Assets (ROA) | -18.41% |
| ROA (5Y Average) | -94.16% |
| Asset Turnover | 0.00x |
Scores
AVTX has an Altman Z-Score of 4.00, in the safe zone above 2.99, and a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 4.00 |
|---|---|
| Altman Z Zone | Safe |
| Piotroski F-Score | 1 of 9 |
| Piotroski Strength | Weak |
Income Statement
Revenue of $59.00K over the last 12 months is down 69.27% from the 12 months before.
| Revenue | $59.00K |
|---|---|
| Revenue Growth (YoY) | -69.27% |
| Gross Profit | $59.00K |
| Operating Income | -$95.56M |
| Pretax Income | -$88.49M |
| Net Income | -$88.65M |
| Reported EPS (TTM) | -$2.52 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 90.68% of the $481.43M in total assets.
| Cash and Equivalents | $64.99M |
|---|---|
| Total Debt | $0 |
| Net Cash | $64.99M |
| Net Cash Per Share | $1.18 |
| Working Capital | $376.64M |
| Shareholder Equity | $436.55M |
| Book Value Per Share | $7.93 |
| Tangible Book Value | $426.04M |
| Tangible Book Per Share | $7.74 |
| Total Assets | $481.43M |
| Total Liabilities | $44.88M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | -$63.47M |
|---|---|
| FCF Per Share | -$1.18 |
| Depreciation and Amortization | $1.50M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -161961.02%.
| Gross Margin | 100.00% |
|---|---|
| Operating Margin | -161961.02% |
| Pretax Margin | -149976.27% |
| Net Margin | -150259.32% |
| Gross Margin (5Y Average) | 93.92% |
Growth
Revenue fell 85.16% a year over 3 years.
| Revenue Growth (3Y CAGR) | -85.16% |
|---|---|
| Revenue Growth (5Y CAGR) | -61.19% |
| Book Value Per Share Growth (2Y CAGR) | -29.83% |
Dividends and Yields
AVTX does not pay a dividend.
| Buyback Yield | -3.76% |
|---|---|
| Shareholder Yield | -3.76% |
Stock Splits
The last split was a 1-for-238 reverse split on Dec 29, 2023.
| Last Split Date | Dec 29, 2023 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:238 |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About AVTX
What is AVTX's market cap?
Avalo Therapeutics has a market cap of $448.71M. Its enterprise value, which adds debt and subtracts cash, is $383.72M.
How many shares of AVTX are outstanding?
Avalo Therapeutics has 55.06M shares outstanding. The count is up 293.28% from a year earlier.
Does AVTX pay a dividend?
No. Avalo Therapeutics does not pay a dividend.
How much debt does AVTX have?
Avalo Therapeutics has $0 of total debt and $64.99M of cash and equivalents, a net cash position of $64.99M.
AVTX pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors